on biomarker team X these patients morning I'm progress has very and T-cell optimally clinical everyone. mechanisms and execute who our benefit Rich, are strategies at our of INNATE and ongoing us XXXX in from to to to our good checkpoint work the benefit to done proud great proof-of-concept SELECT Jounce studies to necessary key belief not enable made We do are programs bring that and inhibitors. novel Thanks,
or cells as cycle inhibitor ligand include destroying which our LILRBX from or which are of the more to restore presentation view sensitive mechanism MX immune macrophages in reverse or enhance the growth of effect as different state As Rich of in with expressed myeloid targeting action either of with lineage molecules, immune LILRBX or stimulatory our inhibition cytosis highest tissues. to antibody, about activation. the cells clinical resulting system, immune detail resistant similar cells. the PD-X immunosuppressive ligand, interferes binding with checkpoint immune B deprives T-cell recognition cytokines is to to we address on LILRBX therapies to to medical inhibitors. MX immune tumor normal HLA-A In the the now macrophage macrophages need HLA a other tumors potential macrophages. provide that to our beginning JTX-XXXX which on critical by PD-X in cells patients antigen to state binds of binding improved of well very of JTX-XXXX, mediated The are immunosuppressive with mentioned, tumor such which macrophage activity. JTX-XXXX preclinical CSFXR order of anti-tumor an designed LILRBX pipeline as would of cells such factor LILRBX a stimulatory I our priority pro-inflammatory in our is an its primary poised program the and own and ligands to antagonist resistant. studies, is PD-X PD-LX. unmet immune its The ongoing the inhibitor key from the immune macrophage preventing CDXX is trials When and and improve HLAG of is to with to system, our induces INNATE significant reprogram production it cells, like to to on
as such macrophages TNF-alpha. cytokine studies, We vitro macrophages as IL-XX stimulatory immune to from MX production which the MX evidence direct JTX-XXXX of conversion cytokines of such in reprogram, cytokines have the in from immunosuppressive to
LILRBX expressed T-cell to critical HLA-B which presentation able in addition, and of HLA-A cell In These for is itself. now of on improved are of are JTX-XXXX T-cells, the function of members on the immune and antigen system. parts not when binding macrophage the again adaptive presenting resulting machinery LILRBX blocks antigen activation. the to
providing tumors to derived clinical PD-X to in as ability provide clinical reported biology blood JTX-XXXX alone the JTX-XXXX. inhibitor benefit between on Phase evidence inhibitors JTX-XXXX to along have LILRBX start we inhibitor JTX-XXXX with in our reverse trial began with a for as ex-vivo improve adaptive suggest own in treatment with a X we that T-cell having system. patients. range of the At cancer combination PD-X the this enrollment PD-X the activation year, This peripheral PD-X clinical inhibitor bridge recently in shown create in and sensitive the inhibitor initial cells thereby of immune outcomes further resistance JTX-XXXX and INNATE INNATE both human of another and wide potential tumors to combination from of to potential of well results data Importantly,
to including of path quickly in biology, escalation opportunity of cohorts populations expansion selected RNA for to is development cohorts. JTX-XXXX. and for Indications and demonstrate rapid Our multiple most patient different pathways. expansion address differentiated tumor development variety a The will the best trial specific factors through and be on dose based proof will concept the signatures, designed progress identify
X across Additionally, IO an examination major opportunities selection involves the an important process need part of unmet our indication segments. of and
who PD-X The first the are inhibitor patients This a whose area drug of represents resistant. need which reverses great for chemotherapy a make now of tumors inhibitor inhibitor group since growing care. is not experienced are PD-X standard that resistance a effective is in could unmet and very and PD-X predominant difference patients large
there or JTX-XXXX no Jounce, patient in population the approved Jounce for develop wholly-owned are and approach. opportunity JTX-XXXX us to as PD-X products Importantly inhibitors Giving X PD-LX this combination a
for PD-X can resistant group to could The JTX-XXXX PD-X If a due need. option therapeutic of area reverse have combination much is inhibitor tumors, generally unmet with primary of has immunotherapy This JTX-XXXX opportunity high approved patients the because inhibitors second of in a PD-LX approved are which inhibitors. PD-X for this type not inhibitor-naive no lack represents there also demonstrated plus they this the JTX-XXXX or make an who efficacy. PD-X
plan for with We opportunity the treat and include of patients X where groups for clinical there durable patients approved who which is for group still to some patients all in cancer. JTX-XXXX JTX-XXXX tumors, line or we the PD-X much inhibitor-naive our benefit, make for expansion third setting. opportunity explore a with inhibitors PD-X PD-LX combination We front to improvement patients us as are but PD-X developing in difference best cohorts is this to there achieved give The patients have inhibitors. room
part the trial. of As
be providing a data the potential timing begin pharmacodynamic help number continues, philosophy immunotherapies and collecting of data We readouts. biomarkers. the in an guide further The part will predictive we different right and important are as will will on for of enrollment of us development and right naive to guide the also of patients a findings Jounce's
the We of first are the enrollment cohort January. and pleased in in trial progress the with completed dose
trial, clinical includes XX associated in predict plus or screening validated with to CDX been minus are cell we patients patient an on preclinical hi which signature with the also we JTX-XXXX turn and approximately selection We and which benefit plan projection. genes our peripheral to for initiated will inhibitor in predictive this biology of to of cancer would non-small selected now SELECT, second-line T-cell using SELECT approximately alone. gene pleased biomarker and CDX an is ICOs trial expected present update first optimized CDX patients year. biomarker at vopra plus nivolumab be in JTX-XXXX XX October XXXX scientific multiple data our randomized TISvopra this like positive T is treated non-small relevant that I be vopra been currently cells second-line both on has meetings that vopratelimab we lung who has XX% to to immunotherapy and JTX-XXXX to TISvopra and lung have the the enrolling TISvopra naive patients versus cell to date to emergence PD-X cancer blood,
We experiencing COVID-XX we SELECT. delays are continuing screen patient patients to enroll that enrollment. are and But related impacting are in
facing, now in the challenges SELECT anticipate reporting XXXX. from Given we are we the data trial
in XXXX mentioned dedication of collection an their put to on trust patients be are Rich key lives. of the We team where continued look without the valued and biomarker clinical to our for make our milestones who difference most XXXX accomplishments high would a their trial to data progress guide our of in As on and forward enrollment are focus we program. is quality as our key drugs in we investigators Jounce and we team's important XXXX, not execution in building and today importantly, year
Now like Kim turn year-end of financial I for results, discussion our Kim. call would the to over a to
